RxDoctor Payments Data

Barbara Muniz, APRN

Family · Lutz, FLNPI 1093163040

Payments from drug & device makers

$506in general payments, 2019–2025

Across 29 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$135
  • Amgen$107
  • Novo Nordisk$101
  • GSK$75
  • Pfizer$38
  • Lilly USA, LLC$32
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$506100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences8$135
Amgen6$107
Novo Nordisk6$101
GSK4$75
Pfizer2$38
Lilly USA, LLC2$32
Novartis1$17

How this compares

$506 in reported general payments places this provider in the 55th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$61,665
Medicare patients
184
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$83,933
RybelsusSemaglutide47$82,612
EliquisApixaban44$49,189
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$36,924
TrulicityDulaglutide11$14,779
MounjaroTirzepatide11$12,055
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$6,463
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$6,201
Albuterol Sulfate HfaAlbuterol Sulfate87$3,772
LantusInsulin Glargine,hum.Rec.Anlog20$3,320
Levothyroxine Sodium186$2,959
Atorvastatin Calcium329$2,897
Omeprazole137$1,732
SynthroidLevothyroxine Sodium13$1,688
Fluticasone Propionate99$1,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$101$166,545114 claims
PfizerEliquis$38$49,18944 claims
GSKTrelegy Ellipta$75$36,92436 claims
Lilly USA, LLCTrulicity, Mounjaro$32$26,83322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 14,618 family providers in Florida.

Other family in Lutz

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →